Monoclonal antibody manufacturing: Cost benefits of hybrid disposable systems

BioProcess International

Volumn 9, Issue 9, 2011, Pages 12-17

  Sinclair, Andrew ^a   Monge, Miriam ^a  

^a BioPharm Services UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

CELL CULTURE; COST BENEFIT ANALYSIS; DRUG INDUSTRY; HYBRID CELL; LABORATORY; MICROTECHNOLOGY; RISK ASSESSMENT; SHORT SURVEY;

EID: 80054766239     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Short Survey

References (2)

1. Sinclair A, Monge M. Delivering Affordable Biologics from Gene to Vial.BioProcess Int. 8(3) 2010: 16-19.
2. Langer E. Trends in Capacity Utilization for Therapeutic Monoclonal Antibody Production. mAbs 1(2) 2009: 151-156.